TrialWiener klinische Wochenschrift2021

Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease.

Stefan Traussnigg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.